<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604718</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-POL-2017-01</org_study_id>
    <secondary_id>PRO-BEL-2017-01</secondary_id>
    <nct_id>NCT03604718</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata</brief_title>
  <official_title>Observational Prospective Study to Assess the Safety and Effectiveness Profile of Beltavac® Polymerized With Alternaria Alternata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probelte Pharma S.L.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probelte Pharma S.L.U.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy
      With Beltavac® Polymerized With Alternaria alternata in allergic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective open multi-centre non-interventional study assess the safety and
      effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac®
      Polymerized in Alternaria alternata allergic patients (children and adults) in routine
      medical care.

      Patients receive a rush schedule administration every month for a year. They attend at least
      4 study visits to inform about the adverse reactions, the self reported symptoms and the
      medication intake.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of treatment-related local and systemic reactions</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjuntivitis medication intake</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue Scale Score</measure>
    <time_frame>1 year</time_frame>
    <description>Psycometric scale that assesses the global allergic disease discomfort. It is a 10 cm line representing severity from 0:&quot;no symptoms&quot; to 10 &quot;highest level of symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgE and IgG4 specific quantification</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rhinoconjunctivitis With or Without Allergic Asthma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Beltavac® Polymerized with Alternaria alternata</intervention_name>
    <description>Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from the age of 5 on, who suffer from allergic rhinoconjunctivitis caused by
        Alternaria alternata
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of the age of 5 years and older suffering from a clinically relevant
             Alternaria alternata induced allergic rhinitis

          -  Positive skin testing or IgE determination to the relevant allergen

        Exclusion Criteria:

        Patients suffering from acute or chronic infections or inflammations Patients suffering
        from uncontrolled asthma Patients with a known autoimmune disease Patients with active
        malignant disease Patients requiring beta-blockers Patients having any contraindication for
        the use of adrenaline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inmaculada Buendía Jiménez, DVM</last_name>
    <phone>+34 968 858577</phone>
    <email>inmaculadabuendia@probeltepharma.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcos Peñalver, PhD</last_name>
    <phone>+34 968 858577</phone>
    <email>drpenalver@probeltepharma.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitary Hospital of Vic</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Serra, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Fedear</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Ayguadé, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Torrejon</name>
      <address>
        <city>Torrejón De Ardoz</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Yago, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cartagena</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Julio Huertas, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica de Alergia Mar Jiménez Lara</name>
      <address>
        <city>Talavera De La Reina</city>
        <state>Toledo</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mar Jiménez, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allergo Centre</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Malet, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Cenvi Medic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Tubella, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Torrelodones</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Baquero, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ojeda Clinic</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Ojeda, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reina Sofia Universitary Hospital</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Miralles, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Alergologica Dr Moral</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Javier Moral, DM</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

